Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2014-11-06 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于收购苏州金盟生物技术有限公司股权暨增资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of a 24.06% equity stake in Suzhou Jinmeng Biotechnology Co., Ltd. and a planned capital increase of RMB 150 million over two years. It includes transaction details, parties involved, financial data of the target company, agreements, purpose and impact of the transaction, risk warnings, and references to board resolutions and regulatory requirements. The content focuses on a capital investment and acquisition update rather than a financial report, earnings release, or management discussion. It is not a full annual or interim report, nor a regulatory certification or voting result. The document fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through acquisition and capital injection.
2014-11-06 Chinese
关于收购成都金凯生物技术有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Xilintai Pharmaceutical Co., Ltd. regarding the acquisition of 80% equity in Chengdu Jinkai Biotechnology Co., Ltd. It details the transaction overview, parties involved, financial data of the target company, transaction terms, strategic rationale, and risk disclosures. The content focuses on a specific capital transaction (an acquisition) and does not contain comprehensive financial statements or periodic financial results. It is not a full annual or interim report, nor an earnings release or management discussion. The document is a formal announcement of a financing/capital transaction (acquisition of shares) by the company. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (4906 characters) and detailed transaction information support this classification with high confidence.
2014-11-06 Chinese
关于收购深圳市信立泰资产管理有限公司股权暨阿利沙坦酯原料药新药技术的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of equity in a subsidiary and the transfer of new drug technology by Shenzhen Xilintai Pharmaceutical Co., Ltd. It includes transaction details, parties involved, financial figures, approvals, and risk disclosures. The content focuses on a capital transaction and strategic cooperation agreements, with no indication of financial statements, audit opinions, or regulatory certifications. It is not a full annual or interim report, nor an earnings release or management discussion. The document is a formal announcement of a capital/financing update related to acquisition and technology transfer, fitting the Capital/Financing Update (CAP) category.
2014-11-06 Chinese
关于独立董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director from the company's board. It details the resignation date, reasons, and the impact on the board composition. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the resignation notice. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2014-10-29 Chinese
2014年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2014 Third Quarter Report" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed financial data for the third quarter of 2014, including main accounting data, financial indicators, shareholder information, important matters, and performance forecasts. The presence of quarterly financial statements and substantive financial data confirms it is a comprehensive interim report for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2014
2014-10-20 Chinese
2014年第三季度报告全文
Interim / Quarterly Report Classification · 98% confidence The document is titled as the "2014 Third Quarter Report" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed financial data including consolidated and parent company balance sheets, income statements, cash flow statements, and notes on accounting policies and shareholder information. The presence of quarterly financial data, management's discussion of financial indicators, and detailed financial statements indicates this is a comprehensive interim financial report for a period shorter than a full fiscal year. The document length is substantial (15,000 characters), and it contains actual financial statements and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2014
2014-10-20 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.